eNewsroom for: InnFocus Inc.

News from InnFocus Inc.:

Santen to Acquire InnFocus, Developer of "MicroShunt" Glaucoma Implant Device

OSAKA, Japan and MIAMI, July 19, 2016 /PRNewswire/ — Santen Pharmaceutical Co., Ltd. (hereinafter, "Santen") and InnFocus, Inc. (hereinafter, "InnFocus") today announced that the two companies have entered into a definitive agreement under which Santen will acqui…

InnFocus MicroShunt® 3-Year Results of a Long Term Clinical Trial Show Long Lasting IOP Reduction

Patient IOP Reduced average of 55% to 10.7mm Hg MIAMI, Jan. 27, 2016 /PRNewswire/ — Glaucoma patients treated in a prospective clinical trial with the InnFocus MicroShunt® Drainage System and followed for over three years experienced significant reduction in both Intraocular Pressure (IO…

InnFocus Closes $33.9 Million Series C Financing

Final phase for FDA study on InnFocus MicroShunt® glaucoma drainage system has begun MIAMI, Dec. 22, 2015 /PRNewswire/ — InnFocus, Inc. reports it has closed its Series C financing, which raised additional monies to total $33.9 million. The Company is developing the InnFocus MicroShunt® (IM…

FDA Approves InnFocus Glaucoma Study Expansion

Final Clinical Testing Phase to Begin MIAMI, Nov. 10, 2015 /PRNewswire/ — InnFocus Inc. announces it has received approval from the U.S. Food and Drug Administration (FDA) to expand to the pivotal final phase of its randomized clinical study comparing its InnFocus Microshunt® Glaucoma Draina…

InnFocus Inc. Names Randy Lindholm Executive Chairman of the Board

The move positions the glaucoma company for domestic and international growth MIAMI, Oct. 28, 2015 /PRNewswire/ — InnFocus, Inc. reports that Randy Lindholm has been named Executive Chairman of the Board of Directors. The Company is developing the InnFocus MicroShunt® GLAUCOMA DRAINAGE S…

InnFocus Concludes $32.8 Million Financing

Series C Funding To Be Used To Pursue Final FDA Approval MIAMI, Sept. 30, 2015 /PRNewswire/ — InnFocus, Inc. reports the conclusion of a $32.8 million Series C financing. The Company is developing the InnFocus MicroShunt® glaucoma drainage system to treat all stages of primary open angle glau…

First Glaucoma Patients Treated in the Netherlands Using InnFocus MicroShunt®

Large Reduction in Both Intraocular Pressure and Glaucoma Medication Use Noted MIAMI, July 13, 2015 /PRNewswire/ — InnFocus, Inc. reports that the first 3 surgeries in the Netherlands to treat glaucoma using the InnFocus MicroShunt® glaucoma drainage implant have been conducted.  The In…

InnFocus Expands Board of Directors and Responsibilities

Current Director Randy Lindholm Named Chair; Tim Willis Joins Board MIAMI, April 16, 2015 /PRNewswire/ — InnFocus, Inc. reports Director Randy Lindholm has been named Chairman of the Board. Mr. Lindholm was previously Chairman of the Board and CEO of Vidamed, until it was acquired by Medtroni…

InnFocus FDA Phase One Enrollment Reaches 75 Patient Filing Milestone

InnFocus MicroShunt Glaucoma Drainage Implant Showing Promising Results in Other Studies MIAMI, April 13, 2015 /PRNewswire/ — InnFocus Inc. reports that treatments for its U.S. Food and Drug Administration (FDA) Phase One clinical trial of the InnFocus MicroShunt® glaucoma drainage imp…

InnFocus MicroShunt® Glaucoma Series Of 82 Patients Show Excellent Results

SAN FRANCISCO, Feb. 9, 2015 /PRNewswire/ — InnFocus Inc. Chief Executive Officer Russ Trenary reports on a series of 82 patients that have been implanted with the InnFocus MicroShunt® outside the United States. The patients experienced a mean reduction in Intraocular Pressure (IOP) from a p…

First Glaucoma Patients Treated in Spain Using InnFocus MicroShunt®

MIAMI, Jan. 20, 2015 /PRNewswire/ — InnFocus, Inc. reports that the first surgeries using the InnFocus MicroShunt® glaucoma drainage implant in Spain have been successfully conducted. Two surgeries were performed at the Hospital Clinico San Carlos in Madrid, Spain. Photo – htt…

InnFocus MicroShunt® Continues to Show Excellent Results

CEO Tells San Francisco Forum That It Treats the Largest Glaucoma Patient Segment SAN FRANCISCO, Jan. 12, 2015 /PRNewswire/ — InnFocus, Inc. reports the InnFocus MicroShunt® has now been used in more than 100 glaucoma surgeries worldwide, in the current configuration and surgical technique,…

InnFocus Featured at the Ophthalmology Innovation Summit In Chicago

InnFocus MicroShunt® showing promising results in reducing IOP in glaucoma patients. CHICAGO, Oct. 17, 2014 /PRNewswire/ — InnFocus, Inc., reported on results of 59 glaucoma patients treated outside the United States for up to 3 years with the InnFocus MicroShunt® at the 2014 Ophthalmolo…

InnFocus MicroShunt™ Shows Promising Glaucoma Results at ESCRS

IOP Levels Stable and Below 14mmHG after one year in another series MIAMI, Sept. 22, 2014 /PRNewswire/ — InnFocus, Inc. reported today that it shared one year results from 34 patients treated, utilizing the current surgical technique for the InnFocus MicroShunt ™ glaucoma drainage implant, a…

First Surgery in Japan Using InnFocus MicroShunt™

Shirato Eye Clinic of Tokyo is first Japanese center to use the MicroShunt for Glaucoma MIAMI, Sept. 10, 2014 /PRNewswire/ — InnFocus, Inc. reported today that the first two surgeries have been conducted in Japan in a clinical investigational study using the InnFocus MicroShunt™ glaucoma d…

Russ Trenary to Lead InnFocus, Inc.

Veteran Ophthalmology Executive Will Guide Development and Approval of Exciting New Glaucoma Surgical Device. MIAMI, Oct. 1, 2013 /PRNewswire/ — Russ Trenary has been named President and Chief Executive Officer of Miami-based InnFocus, Inc., a privately held medical device company w…